By: The Trek News Desk
In a landmark move, the World Health Organisation (WHO) has officially recommended the use of GLP-1–based medications for long-term obesity management in adults. The guidance signals a major shift in how the global health body categorises obesity, no longer as a simple “lifestyle issue,” but as a complex, preventable, and treatable chronic disease.
The updated recommendations were published on Monday in the medical journal JAMA, defining long-term use as at least six months of continuous treatment.
“A New Chapter in How We View Obesity” – WHO
In its statement, WHO noted that GLP-1 therapies reflect more than scientific progress; they represent a change in how the world conceptualises obesity and those who struggle with it.
The organisation emphasised, however, that medication alone cannot address the global obesity crisis. Genetics, rising stress levels, and increasing consumption of highly processed foods all play a significant role in driving global obesity rates.
How GLP-1 Drugs Work
GLP-1 agonists imitate a naturally occurring hormone that alerts the brain when the stomach is full. The effect:
- Reduced appetite
- Better control over food intake
- Noticeable weight loss
Over recent years, these drugs have surged in popularity as studies show they may also reduce risks linked to obesity, including:
- High blood pressure
- Heart attacks
- Stroke
From Diabetes Medicines to Obesity Treatment
In September, the WHO added certain GLP-1 drugs to its Essential Medicines List for diabetes treatment, but stopped short of approving them for obesity alone.
Now, following requests from member nations and an extensive review by a panel of metabolic health and pharmacology experts, the WHO has issued a conditional recommendation for their use in obesity care.
This means:
- Benefits currently outweigh known risks
- But long-term safety and efficacy data remain limited
WHO called for:
- Expanded long-term clinical research
- Lower prices to ensure wider access
The Cost Barrier: Popular Drugs Exceed $1,000 Per Month in the U.S.
In the United States, sought-after weight loss drugs like Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy cost over $1,000 per month, pricing that remains a major obstacle for millions.
Recent announcements from the Trump administration suggest that new agreements with pharmaceutical companies may reduce out-of-pocket costs for people using Medicare or Medicaid, or those without insurance.
What Happens Next?
WHO’s guidelines frequently influence national policies, meaning several countries may soon update their obesity treatment frameworks.
With obesity recognised as a growing global health emergency, experts anticipate that GLP-1 medications will play an increasingly prominent role in treatment plans worldwide.
The new guidance may mark only the beginning of a much larger transformation in how the world confronts obesity, scientifically, socially, and economically.
Source: News Agencies
